期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小剂量反应停联合地塞米松治疗老年多发性骨髓瘤临床疗效分析

Evaluating the Therapeutic Effect on Old Patients with Multiple Myeloma of Thalidomide and Dexamethasone in Low Dose
在线阅读 下载PDF
导出
摘要 目的:探讨小剂量反应停联合地塞米松治疗初治多发性骨髓瘤(mulitiple myeloma,MM)的疗效和不良反应。方法:17例治疗组患者予小剂量反应停(100mg/d起,每周增加50mg/d,2周后增至200mg/d),同时联合地塞米松40mg/d(d1~4,9~12,17~20)1个月1疗程,至少3个月。与前期给予2个疗程标准VAD方案治疗的18例患者进行历史对照。结果:治疗组与对照组相比较总有效率差异无统计学意义(P>0.05),但不良反应发生率明显小于对照组。结论:小剂量反应停联合地塞米松作为初治50岁以上MM患者的治疗方案是安全有效的。 Objective:To evaluate the therapeutic effect on old patients with multiple myeloma of thalidomide and dexamethasone in low dose and its side effect.Methods: 17 cases of treatment group are treated with thalidomide and dexamethasone for no less than three months,and compared with the 18 cases of control group treated with two courses of standard VAD protocol.Results: There has no significant difference of effective rate between this two groups(P>0.05),but the incidence rate of side effect in treatment gro...
作者 徐城林
机构地区 攀枝花市第二人民医院血液科
出处 《四川省卫生管理干部学院学报》 2008年第3期163-165,共3页 Journal of Sichuan Continuing Education College of Medical Sciences
关键词 小剂量反应停 地塞米松 多发性骨髓瘤 Thalidomide in Low Dose Dexamethasone Multiple Myeloma.
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1[1]Tosi P,Zamagni E,Cellini C.Thalidomide alone or in combination with dexamethasone in patients with advanced,relaped or refractory multiple myeloam and renal failure[J].Eur J Hacmatol,2004;73(2):98.
  • 2[2]The International Myeloma Working Group.Criteria for the classification of monoelonal gammopathies,multiple myeloma and related disorders:a reportof the Intemfional Myeloma Working Group[J].Br Haematol,2003;121:749.
  • 3[5]Rajkumar SV,Witzig TE.A review of angiogenesis and antiangiogenie therapy with thalidomide in multiple myeloma[J].Cancer Treat Rev,2000;26(5):351.
  • 4[6]Kawano M,Hirano T,Matsuda T,et al.Auteerine generation and repuirement of BSF-2/IL-6 for human multiple myelomas[J].Nature,1988;332(6159):83.
  • 5[7]Singhal S,Mehta J,Desikan R,et al.Antitumor activity of thalidomide inrefractory multiple myeloma[J].N Engl J Med.1999;341(21):1565.
  • 6[8]Davies FE,Raje N,Hideshima T,et al.Thalidomide and immunomodu latory derivatives augment natural killer cell cytotoxicity in multiple myeloma[J].Blood,2001;98(1):210.
  • 7[9]Weber D,Rankin K,Gavino M,et al.Thalidomide alone or with dexamethasone for previously untreated multiple myeloma[J].J Clin Oncol,2003;21(1):16.
  • 8刘丽辉,武永吉.反应停治疗多发性骨髓瘤的机制及临床应用[J].临床血液学杂志,2002,15(3):138-139. 被引量：31

二级参考文献8

  • 1Bellamy W,List A,Grogan T.Expression of VEGF and its receptors in myeloma.Program and abstracts of the Ⅷinternational myeloma workshop[].Canada Reports.2001
  • 2Tosi P,Ronconi S,Zamagni E,et al.Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation[].Haematologica.2001
  • 3Rajkumar S V,Leong T,Roche P C,et al.Prognostic value of bone marrow angiogensis in multiple myeloma[].Clinical Cancer Research.2000
  • 4Schreiber S,Ackermann J,Obermair A,et al.Multiple myeloma with eletion of chromosome 13q is characterized by ineased bone marrow neovascularization[].British Journal of Haematology.2000
  • 5Peuckmann V,Fisch M,Bruera E,et al.Potential novel uses of thalidomide: focus on palliative care[].Drugs.2000
  • 6Celgene.Program and abstracts of the Ⅷinternational myeloma workshop[].Canada Reports.2001
  • 7Faith E D,Noopur R,Teru H,et al.Thalidomide and immunmodulatory derivatives augment natral killer cell cytotoxicity in multiple myeloma[].Blood.2001
  • 8Rajkumar S V,Witzig T E.A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma[].Cancer Treatment Reviews.2000

共引文献30

四川省卫生管理干部学院学报
2008年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部